Elisabeth Leiderman
Fortune : - $ au 31/05/2026
Fortune : - $ au 31/05/2026
Elisabeth Leiderman currently works at Autolus Therapeutics Plc, as Non-Executive Director from 2023 and Dewpoint Therapeutics, Inc., as Chief Financial Officer from 2024.
Dr. Leiderman also formerly worked at bluebird bio, Inc., as Independent Director from 2021 to 2025, Nomura Securities, Inc., as Executive Director from 2013 to 2016, Fortress Biotech, Inc., as VP-Business & Corporate Development from 2007 to 2016, Complexa, Inc., as Chief Business Officer from 2016 to 2020, Decibel Therapeutics, Inc., as Chief Financial & Accounting Officer from 2021 to 2022, and Atsena Therapeutics, Inc., as Chief Financial & Business Officer from 2022 to 2023.
Dr. Leiderman received her undergraduate degree from the University of Pennsylvania, Masters Business Admin degree from The Wharton School of the University of Pennsylvania, and doctorate degree from Sackler School of Medicine.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Directeur/Membre du Conseil | 20/12/2023 |
Dewpoint Therapeutics, Inc.
Dewpoint Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biomolecular condensates biotechnology company | Directeur Financier/CFO | 01/06/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| GENETIX BIOTHERAPEUTICS, INC. | Directeur/Membre du Conseil | 02/06/2025 |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage gene therapy company that develops treatments for inherited retinal diseases that cause blindness | Directeur Financier/CFO | 01/11/2023 |
| DECIBEL THERAPEUTICS, INC. | Directeur Financier/CFO | 07/10/2022 |
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on discovering and developing therapies for the treatment inflammatory and metabolic diseases | Corporate Officer/Principal | 01/08/2020 |
Nomura Securities, Inc. | Directeur/Membre du Conseil | 01/07/2016 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Fortress Biotech, Inc.
Fortress Biotech, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical and biotechnology products | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on discovering and developing therapies for the treatment inflammatory and metabolic diseases | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sackler School of Medicine
Sackler School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Decibel Therapeutics, Inc.
Decibel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops medicines for hearing and balance disorders | Health Technology |
Autolus Therapeutics Plc
Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
Dewpoint Therapeutics, Inc.
Dewpoint Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biomolecular condensates biotechnology company | Health Technology |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage gene therapy company that develops treatments for inherited retinal diseases that cause blindness | Health Technology |
Nomura Securities, Inc. |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national